Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
· In Vitro & In Vivo Diagnostic Substances
RESEARCH SNAPSHOTCardio Diagnostics Holdings, Inc.'s latest supported as-filed period reports revenue of $5,360, 28.3% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -25044.10% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -28.29% · CORE
Level · gp.fundamentals.operating_margin
Raw value -27950.50% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 3039.72% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 454.33% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +0.0% from the comparable as-filed period.
Net income changed +10.8% from the comparable as-filed period.
Operating income changed +10.8% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Operating margin changed -549299 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
CDIO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001079973-26-001153SEC ↗10-QAug 7, 2026Period Jun 30, 20260001079973-26-001016SEC ↗4Jul 2, 2026Period Jun 30, 20260002060369-26-000003SEC ↗4Jul 2, 2026Period Jun 30, 20260002055040-26-000003SEC ↗4Jul 2, 2026Period Jun 30, 20260001950394-26-000003SEC ↗4Jul 2, 2026Period Jun 30, 20260002006956-26-000003SEC ↗10-QMay 15, 2026Period Mar 31, 20260001553350-26-000089SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 30, 2026Filed Jul 2, 2026 | Fung Peter KDirector | Grant Or AwardDirect | 2,854 | $2 | $6,250 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -0.1% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Revenue changed -28.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0002060369-26-000002